Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) and Rein Therapeutics (NASDAQ:RNTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Insider & Institutional Ownership
7.4% of Emmaus Life Sciences shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 35.0% of Emmaus Life Sciences shares are owned by insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Emmaus Life Sciences and Rein Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Emmaus Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Rein Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Earnings & Valuation
This table compares Emmaus Life Sciences and Rein Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Emmaus Life Sciences | $12.45 million | 0.06 | -$7.49 million | ($0.12) | -0.08 |
| Rein Therapeutics | N/A | N/A | -$49.87 million | ($1.96) | -0.57 |
Emmaus Life Sciences has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Emmaus Life Sciences and Rein Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Emmaus Life Sciences | -60.16% | N/A | -34.05% |
| Rein Therapeutics | N/A | -510.35% | -56.38% |
Risk & Volatility
Emmaus Life Sciences has a beta of 9.32, suggesting that its share price is 832% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
Summary
Emmaus Life Sciences beats Rein Therapeutics on 8 of the 13 factors compared between the two stocks.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
About Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
